You are here: Industry Insights > PRIME

News List

Tessa Receives PRIME Designation from EMA for CD30 CAR-T Therapy americanpharmaceuticalreview
January 27, 2021
Tessa Therapeutics announced the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).
Valneva’s Chikungunya Vax Granted PRIME Designation contractpharma
October 22, 2020
Becomes the first company worldwide to advance a chikungunya vaccine candidate into Phase III.
PRIME status for Adaptimmune's synovial sarcoma drug pharmatimes
July 28, 2020
The European Medicines Agency (EMA) has awarded Adaptimmune's ADP-A2M4 PRIME status for the treatment of synovial sarcoma.
Acceleron receives PRIME designation from EMA for Sotatercept in pulmonary arterial hypertension pharmaceutical-business-review
May 06, 2020
Acceleron Pharma said that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
Roche gets PRIME designation for SMA drug in Europe pharmaceutical-technology
December 20, 2018
Roche has secured PRIME designation from the European Medicines Agency (EMA) for its risdiplam (RG7916) medicine to treat spinal muscular atrophy (SMA).
Roche’s SMA drug gets PRIME regulatory status in Europe pharmaphorum
December 19, 2018
Roche is hoping to challenge Biogen with a new treatment for the rare muscle wasting disease spinal muscular atrophy – and the plans just got a boost after European regulators gave it special priority.
Modis Announces PRIME Designation by European Medicines Agency americanpharmaceuticalreview
November 14, 2018
Modis Announces PRIME Designation by European Medicines Agency
PRIME status for Orchard’s gene therapy pharmatimes
October 11, 2018
The European Medicines Agency has granted Orchard Therapeutics’ experimental gene therapy OTL-300 PRIME designation as a potential treatment for the most severe form...
PRIME status for Ignyta’s entrectinib pharmatimes
October 19, 2017
European regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval.